ArticleClinical and experimental nephrology2021

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.

Keitaro Yokoyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.